Kiebish, Michael A.
Cullen, Jennifer
Mishra, Prachi
Ali, Amina
Milliman, Eric
Rodrigues, Leonardo O.
Chen, Emily Y.
Tolstikov, Vladimir
Zhang, Lixia
Panagopoulos, Kiki
Shah, Punit
Chen, Yongmei
Petrovics, Gyorgy
Rosner, Inger L.
Sesterhenn, Isabell A.
McLeod, David G.
Granger, Elder
Sarangarajan, Rangaprasad
Akmaev, Viatcheslav
Srinivasan, Alagarsamy
Srivastava, Shiv
Narain, Niven R.
Dobi, Albert
Funding for this research was provided by:
USUHS-CPDR fund (HU0001-10-2-0002)
Article History
Received: 3 October 2019
Accepted: 23 December 2019
First Online: 7 January 2020
Ethics approval and consent to participate
: Approval from the local ethics committee was obtained before the onset of the study and all the participants provided their consent before starting the study.
: Not applicable.
: MAK, NRN, RS, VA, LOR, LZ, SS, AD, and JC are co-inventors on patent application “Markers for the Diagnosis of Prostate Cancer”. Other authors declare that they have no competing interests.MAK, EM, LOR, EYC, VT, LZ, KP, PS, EG, RS, VA, and NRN are current or former employees of BERG, LLC and have stock options. NRN is co-founder of BERG, LLC.
: The opinions or assertions contained herein are the private ones of the author/speaker and are not to be construed as official or reflecting the views of the Department of Defense, the Uniformed Services University of the Health Sciences or any other agency of the U.S. Government. The identification of specific products, scientific instrumentation, or organization is considered an integral part of the scientific endeavor and does not constitute endorsement or implied endorsement on the part of the author, DoD, or any component agency.